Keywords: آمبریزنتان; Ambrisentan (PubChem CID: 6918493); bosentan sodium (PubChem CID: 44387533); endothelin-1 (PubChem CID: 16132423); and macitentan (PubChem CID: 16004692); Endothelin-1; ET1-receptors; Ambrisentan; Bosentan; Macitentan; Human radial artery; Human pulmonary
مقالات ISI آمبریزنتان (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: آمبریزنتان; Pulmonary arterial hypertension; Human immunodeficiency virus; Ambrisentan; Mutational analysisHipertensión arterial pulmonar; Virus de la inmunodeficiencia humana; Ambrisentan; Análisis mutacional
Keywords: آمبریزنتان; Hipertensión arterial pulmonar; Virus de la inmunodeficiencia humana; Ambrisentan; Análisis mutacionalPulmonary arterial hypertension; Human inmunodeficiency virus Ambrisentan; Mutational analysis
Keywords: آمبریزنتان; Bosentan; Ambrisentan; Sildenafil; Tadalafil; LC–MS/MS
Metabolite characterization of ambrisentan, in in vitro and in vivo matrices by UHPLC/QTOF/MS/MS: Detection of glutathione conjugate of epoxide metabolite evidenced by in vitro GSH trapping assay
Keywords: آمبریزنتان; Ambrisentan; Metabolite characterization; GSH trapping assay; In silico toxicity prediction; UHPLC/QTOF/MS/MS;
Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1)
Keywords: آمبریزنتان; Ambrisentan; Endothelin A receptor antagonist; Pulmonary Hypertension; Phosphodiesterase 5 inhibitor; Combination drug therapy; Outcome assessment;
Combined approach using capillary electrophoresis, NMR and molecular modeling for ambrisentan related substances analysis: Investigation of intermolecular affinities, complexation and separation mechanism
Keywords: آمبریزنتان; BGE; background electrolyte; CMC; critical micelle concentration; γCyD; γ-cyclodextrin; CyD-MEKC; cyclodextrin-modified micellar electrokinetic chromatography; Îδ; 1H chemical shift change; D.S.; degree of substitution; 2-D NOESY; two-dimensional NOE
Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study
Keywords: آمبریزنتان; ambrisentan; pulmonary arterial hypertension; safety; post-authorisation safety study; registry;
Enantioseparation and impurity determination of ambrisentan using cyclodextrin-modified micellar electrokinetic chromatography: Visualizing the design space within quality by design framework
Keywords: آمبریزنتان; Ambrisentan; Capillary electrophoresis; Chiral separation; Experimental design; Impurities; Quality by design;
Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial
Keywords: آمبریزنتان; Ambrisentan; Pulmonary hypertension; Connective tissue diseases; Outcome assessment;
Ambrisentan May Improve Exercise Tolerance and Cardiac Function in Patients With Pulmonary Hypertension
Keywords: آمبریزنتان; 6-minute walking distance; ambrisentan; brain natriuretic peptide; mean pulmonary arterial pressure; pulmonary hypertension; systolic pulmonary artery pressure;
Endothelin Receptors and Their Antagonists
Keywords: آمبریزنتان; Ambrisentan; antagonist; bosentan; endothelin-1; macitentan; sitaxentan;
Hepatotoxicidad en pacientes tratados con antagonistas del receptor de la endotelina: revisión sistemática y metaanálisis de ensayos clÃnicos aleatorizados
Keywords: آمبریزنتان; Bosentán; Ambrisentán; Sitaxentán; Sitaxsentán; Ensayo clÃnico aleatorizado y controlado; Metaanálisis; Reacción hepática; Hepatotoxicidad; Daño hepático; Bosentan; Ambrisentan; Sitaxentan; Sitaxsentan; Randomized controlled trial; Meta-analysis
Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells
Keywords: آمبریزنتان; Bosentan; Ambrisentan; Sildenafil; Tadalafil; Induction;
Comparison of human ETA and ETB receptor signalling via G-protein and β-arrestin pathways
Keywords: آمبریزنتان; ETA; ETB; Endothelin; β-arrestin recruitment; Vasoconstriction; Human pharmacology; Human left ventricle; Sitaxentan; Ambrisentan; BQ123; BQ788; Biased agonist; Biased antagonist;
Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice
Keywords: آمبریزنتان; Endothelin receptors; ETA ETB; Liver; Hepatotoxicity; Antagonist; Portal hypertension; Sitaxentan; Ambrisentan;
Molecular and Cellular PharmacologyDifferential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro
Keywords: آمبریزنتان; Bosentan; Ambrisentan; Pulmonary arterial hypertension; Drug transporter; Drug metabolising enzyme; Induction;
The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension
Keywords: آمبریزنتان; Pulmonary artery hypertension; Endothelin; Endothelin A receptor; Endothelin B receptor; Ambrisentan; Bosentan; Sitaxentan; Endothelin converting enzyme; Vascular remodelling
Endothelin receptor antagonists - their role in pulmonary medicine
Keywords: آمبریزنتان; Pulmonary arterial hypertension; Endothelin-receptor antagonists; Bosentan; Ambrisentan; Sitaxentan; Pulmonary fibrosis;
Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities
Keywords: آمبریزنتان; ambrisentan; bosentan; endothelin receptor antagonist; hepatotoxicity; liver function test; propanoic acid; pulmonary hypertension; serum aminotransferase; sitaxsentan; sulfonamideALT, alanine aminotransferase; APAH, associated PAH; ARIES, Ambrisentan in
No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers
Keywords: آمبریزنتان; ambrisentan; tadalafil; endothelin receptor antagonist (ERA); phosphodiesterase type 5 (PDE-5) inhibitor; pharmacokinetics; pulmonary arterial hypertension (PAH);